A novel therapy for genital herpes engages immune cells to provide significant patient benefits

A phase II clinical trial demonstrated that a new type of treatment for genital herpes, an immunotherapy called GEN-003, may reduce the activity of the virus and the number of days with recurrent herpes. This effect of treatment, given by a series of three injections, appears to last for up to at least one year.